Willner & Heller’s AstraZeneca AZN Stock Holding History

Willner & Heller’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,218	Closed	-$224K	–	163
2025 Q4	$224K	Buy	+1,218	New	+$214K	0.16%	155
2025 Q1	–	Sell	-2,104	Closed	-$276K	–	147
2024 Q4	$276K	Sell	2,104 -225	-10%	-$31.5K	0.24%	127
2024 Q3	$363K	Buy	2,329 +11	+0.5%	+$1.78K	0.32%	105
2024 Q2	$362K	Hold	2,318	–	–	0.35%	99
2024 Q1	$314K	Sell	2,318 -13	-0.6%	-$1.72K	0.31%	108
2023 Q4	$314K	Buy	+2,331	New	+$303K	0.35%	100
2022 Q4	$328K	Sell	2,416 -112	-4%	-$14K	0.47%	83
2022 Q3	$277K	Sell	2,528 -118	-4%	-$15K	0.45%	84
2022 Q2	$350K	Sell	2,646 -154	-6%	-$20.2K	0.54%	65
2022 Q1	$326K	Sell	2,800 -129	-4%	-$15.5K	0.4%	92
2021 Q4	$352K	Buy	+2,929	New	+$345K	0.47%	73

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Willner & Heller's AZN Position: Q1 2026 in Review

Willner & Heller sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,218 shares — an estimated $224K sold.

Willner & Heller first reported a position in AZN in Q4 2021 and held it in 11 quarters. The position peaked at $363K in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Willner & Heller reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Willner & Heller sold 1,218 AstraZeneca shares in Q1 2026, an estimated $224K.
Willner & Heller first reported a position in AstraZeneca in Q4 2021 and held it in 11 quarters.
Willner & Heller's AstraZeneca position peaked at $363K in Q3 2024.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Willner & Heller's 13F filing for Q1 2026, filed 17 Apr 2026.